OBJECTIVE: It has recently been reported that (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for estimation of the chemotherapy effect. Thus, we examined the value of FDG-PET in assessing the efficacy of chemotherapy in advanced pancreatic cancer, and compared this modality with tumor markers (TMs) and CT. PATIENTS AND METHODS: Nineteen patients with unresectable pancreatic adenocarcinoma were enrolled. All patients received chemotherapy with gemcitabine and S-1, an oral derivative of 5-fluorouracil, and underwent FDG-PET, CT, and serological examination for TMs before and after chemotherapy. RESULTS: Standardized uptake value in FDG-PET before treatment and survival time were not correlated. A good prognosis was seen after 1 course of chemotherapy in patients whose tumors were in partial or complete remission as assessed by FDG-PET [median of survival time (MST), 12.5 months] or TMs (MST, 13.5 months), but not in CT responders (MST, 10.3 months). Furthermore, patient prognosis correlated with PET and TM assessment of the best tumor response through all courses. Namely, both PET and TM were useful for the prediction of survival or chemotherapy sensitivity of the patients. CONCLUSION: FDG-PET and TMs can each play an adjunct role to CT for estimating the effect of chemotherapy and predicting survival by distinguishing between responders and non-responders among patients with advanced pancreatic cancer.
OBJECTIVE: It has recently been reported that (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for estimation of the chemotherapy effect. Thus, we examined the value of FDG-PET in assessing the efficacy of chemotherapy in advanced pancreatic cancer, and compared this modality with tumor markers (TMs) and CT. PATIENTS AND METHODS: Nineteen patients with unresectable pancreatic adenocarcinoma were enrolled. All patients received chemotherapy with gemcitabine and S-1, an oral derivative of 5-fluorouracil, and underwent FDG-PET, CT, and serological examination for TMs before and after chemotherapy. RESULTS: Standardized uptake value in FDG-PET before treatment and survival time were not correlated. A good prognosis was seen after 1 course of chemotherapy in patients whose tumors were in partial or complete remission as assessed by FDG-PET [median of survival time (MST), 12.5 months] or TMs (MST, 13.5 months), but not in CT responders (MST, 10.3 months). Furthermore, patient prognosis correlated with PET and TM assessment of the best tumor response through all courses. Namely, both PET and TM were useful for the prediction of survival or chemotherapy sensitivity of the patients. CONCLUSION: FDG-PET and TMs can each play an adjunct role to CT for estimating the effect of chemotherapy and predicting survival by distinguishing between responders and non-responders among patients with advanced pancreatic cancer.
Authors: Nemil Shah; Guihua Zhai; Joseph A Knowles; Cecil R Stockard; William E Grizzle; Naomi Fineberg; Tong Zhou; Kurt R Zinn; Eben L Rosenthal; Hyunki Kim Journal: Mol Imaging Biol Date: 2012-04 Impact factor: 3.488
Authors: Avani S Dholakia; Muhammad Chaudhry; Jeffrey P Leal; Daniel T Chang; Siva P Raman; Amy Hacker-Prietz; Zheng Su; Jonathan Pai; Katharine E Oteiza; Mary E Griffith; Richard L Wahl; Erik Tryggestad; Timothy Pawlik; Daniel A Laheru; Christopher L Wolfgang; Albert C Koong; Joseph M Herman Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-18 Impact factor: 7.038
Authors: Dushyant V Sahani; Pietro A Bonaffini; Onofrio A Catalano; Alexander R Guimaraes; Michael A Blake Journal: Radiographics Date: 2012 Jul-Aug Impact factor: 5.333
Authors: Amarnath Challapalli; Tara Barwick; Rachel A Pearson; Shairoz Merchant; Francesco Mauri; Elizabeth C Howell; Katherine Sumpter; Ross J Maxwell; Eric O Aboagye; Rohini Sharma Journal: Eur J Nucl Med Mol Imaging Date: 2015-02-12 Impact factor: 9.236
Authors: Gregory L Beatty; Drew A Torigian; E Gabriela Chiorean; Babak Saboury; Alex Brothers; Abass Alavi; Andrea B Troxel; Weijing Sun; Ursina R Teitelbaum; Robert H Vonderheide; Peter J O'Dwyer Journal: Clin Cancer Res Date: 2013-08-27 Impact factor: 12.531
Authors: Hye Jin Choi; Chang Moo Kang; Woo Jung Lee; Si Young Song; Arthur Cho; Mijin Yun; Jong Doo Lee; Joo Hang Kim; Jae-Hoon Lee Journal: Yonsei Med J Date: 2013-11 Impact factor: 2.759